Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
8th February 2021 | Advisors Llc Perceptive | 1,250,000 | Open or private purchase | $16.00 | $20,000,000.00 |
8th February 2021 | Advisors Llc Perceptive | 2,941,769 | Conversion of derivative | $0.00 | |
8th February 2021 | Advisors Llc Perceptive | 1,770,600 | Conversion of derivative | $0.00 | |
8th February 2021 | Advisors Llc Perceptive | 2,857,795 | Conversion of derivative | $0.00 | |
28th January 2021 | Advisors Llc Perceptive | 4,219,409 | Open or private purchase | $2.37 | $9,999,999.33 |
25th January 2021 | Advisors Llc Perceptive | 311,111 | Open or private purchase | $22.50 | $6,999,997.50 |
22nd January 2021 | Advisors Llc Perceptive | 285,151 | Open or private sale | $8.16 | $2,326,832.16 |
22nd January 2021 | Advisors Llc Perceptive | 550,000 | Open or private sale | $1.48 | $814,000.00 |
22nd January 2021 | Advisors Llc Perceptive | 33,849 | Open or private sale | $8.95 | $302,948.55 |
21st January 2021 | Advisors Llc Perceptive | 674,352 | Open or private sale | $1.68 | $1,132,911.36 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Kadmon Holdings, Inc. is a biopharmaceutical company. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir and Abacavir.
26th February 2021
19th February 2021